ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Refractory Multiple Myeloma Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-32P14921
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Refractory Multiple Myeloma Market Research Report 2023
BUY CHAPTERS

Global Refractory Multiple Myeloma Market Research Report 2025

Code: QYRE-Auto-32P14921
Report
May 2025
Pages:77
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Janssen Global Services, LLC
Gilead Sciences Inc
Fresenius Kabi
GSK
Novartis
Genentech Inc
Teva Pharmaceutical Industries Ltd
Bristol–Myers Squibb
Takeda Pharmaceutical Company Limited

Refractory Multiple Myeloma Market

The global market for Refractory Multiple Myeloma was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Refractory Multiple Myeloma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Refractory Multiple Myeloma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Refractory Multiple Myeloma in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Refractory Multiple Myeloma include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited, Genentech, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Refractory Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Refractory Multiple Myeloma.
The Refractory Multiple Myeloma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Refractory Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Refractory Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Refractory Multiple Myeloma Market Report

Report Metric Details
Report Name Refractory Multiple Myeloma Market
Segment by Type
Segment by Application
  • Hospital
  • Specialty Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited, Genentech, Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Refractory Multiple Myeloma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Refractory Multiple Myeloma Market report?

Ans: The main players in the Refractory Multiple Myeloma Market are Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited, Genentech, Inc.

What are the Application segmentation covered in the Refractory Multiple Myeloma Market report?

Ans: The Applications covered in the Refractory Multiple Myeloma Market report are Hospital, Specialty Clinic, Others

What are the Type segmentation covered in the Refractory Multiple Myeloma Market report?

Ans: The Types covered in the Refractory Multiple Myeloma Market report are Proteosome Inhibitor, Immunomodulators, Anti-CD38 Monoclonal Antibody, Others

Recommended Reports

Hematologic Malignancies

Solid and CNS Tumors

Related Blood Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Refractory Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Proteosome Inhibitor
1.2.3 Immunomodulators
1.2.4 Anti-CD38 Monoclonal Antibody
1.2.5 Others
1.3 Market by Application
1.3.1 Global Refractory Multiple Myeloma Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Refractory Multiple Myeloma Market Perspective (2020-2031)
2.2 Global Refractory Multiple Myeloma Growth Trends by Region
2.2.1 Global Refractory Multiple Myeloma Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Refractory Multiple Myeloma Historic Market Size by Region (2020-2025)
2.2.3 Refractory Multiple Myeloma Forecasted Market Size by Region (2026-2031)
2.3 Refractory Multiple Myeloma Market Dynamics
2.3.1 Refractory Multiple Myeloma Industry Trends
2.3.2 Refractory Multiple Myeloma Market Drivers
2.3.3 Refractory Multiple Myeloma Market Challenges
2.3.4 Refractory Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Refractory Multiple Myeloma Players by Revenue
3.1.1 Global Top Refractory Multiple Myeloma Players by Revenue (2020-2025)
3.1.2 Global Refractory Multiple Myeloma Revenue Market Share by Players (2020-2025)
3.2 Global Refractory Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Refractory Multiple Myeloma Revenue
3.4 Global Refractory Multiple Myeloma Market Concentration Ratio
3.4.1 Global Refractory Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Refractory Multiple Myeloma Revenue in 2024
3.5 Global Key Players of Refractory Multiple Myeloma Head office and Area Served
3.6 Global Key Players of Refractory Multiple Myeloma, Product and Application
3.7 Global Key Players of Refractory Multiple Myeloma, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Refractory Multiple Myeloma Breakdown Data by Type
4.1 Global Refractory Multiple Myeloma Historic Market Size by Type (2020-2025)
4.2 Global Refractory Multiple Myeloma Forecasted Market Size by Type (2026-2031)
5 Refractory Multiple Myeloma Breakdown Data by Application
5.1 Global Refractory Multiple Myeloma Historic Market Size by Application (2020-2025)
5.2 Global Refractory Multiple Myeloma Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Refractory Multiple Myeloma Market Size (2020-2031)
6.2 North America Refractory Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Refractory Multiple Myeloma Market Size by Country (2020-2025)
6.4 North America Refractory Multiple Myeloma Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Refractory Multiple Myeloma Market Size (2020-2031)
7.2 Europe Refractory Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Refractory Multiple Myeloma Market Size by Country (2020-2025)
7.4 Europe Refractory Multiple Myeloma Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Refractory Multiple Myeloma Market Size (2020-2031)
8.2 Asia-Pacific Refractory Multiple Myeloma Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2020-2025)
8.4 Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Refractory Multiple Myeloma Market Size (2020-2031)
9.2 Latin America Refractory Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Refractory Multiple Myeloma Market Size by Country (2020-2025)
9.4 Latin America Refractory Multiple Myeloma Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Refractory Multiple Myeloma Market Size (2020-2031)
10.2 Middle East & Africa Refractory Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2020-2025)
10.4 Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Details
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Introduction
11.1.4 Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Teva Pharmaceutical Industries Ltd. Company Details
11.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Introduction
11.2.4 Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.2.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.3 Pfizer Inc.
11.3.1 Pfizer Inc. Company Details
11.3.2 Pfizer Inc. Business Overview
11.3.3 Pfizer Inc. Refractory Multiple Myeloma Introduction
11.3.4 Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.3.5 Pfizer Inc. Recent Development
11.4 Janssen Global Services, LLC
11.4.1 Janssen Global Services, LLC Company Details
11.4.2 Janssen Global Services, LLC Business Overview
11.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Introduction
11.4.4 Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.4.5 Janssen Global Services, LLC Recent Development
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Details
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Introduction
11.5.4 Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.5.5 Gilead Sciences, Inc. Recent Development
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Company Details
11.6.2 Fresenius Kabi Business Overview
11.6.3 Fresenius Kabi Refractory Multiple Myeloma Introduction
11.6.4 Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.6.5 Fresenius Kabi Recent Development
11.7 GSK plc.
11.7.1 GSK plc. Company Details
11.7.2 GSK plc. Business Overview
11.7.3 GSK plc. Refractory Multiple Myeloma Introduction
11.7.4 GSK plc. Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.7.5 GSK plc. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Refractory Multiple Myeloma Introduction
11.8.4 Novartis AG Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Details
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.9.5 Takeda Pharmaceutical Company Limited Recent Development
11.10 Genentech, Inc.
11.10.1 Genentech, Inc. Company Details
11.10.2 Genentech, Inc. Business Overview
11.10.3 Genentech, Inc. Refractory Multiple Myeloma Introduction
11.10.4 Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025)
11.10.5 Genentech, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Janssen Global Services, LLC
Gilead Sciences Inc
Fresenius Kabi
GSK
Novartis
Genentech Inc
Teva Pharmaceutical Industries Ltd
Bristol–Myers Squibb
Takeda Pharmaceutical Company Limited
List of Tables
 Table 1. Global Refractory Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Proteosome Inhibitor
 Table 3. Key Players of Immunomodulators
 Table 4. Key Players of Anti-CD38 Monoclonal Antibody
 Table 5. Key Players of Others
 Table 6. Global Refractory Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Refractory Multiple Myeloma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Refractory Multiple Myeloma Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Refractory Multiple Myeloma Market Share by Region (2020-2025)
 Table 10. Global Refractory Multiple Myeloma Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Refractory Multiple Myeloma Market Share by Region (2026-2031)
 Table 12. Refractory Multiple Myeloma Market Trends
 Table 13. Refractory Multiple Myeloma Market Drivers
 Table 14. Refractory Multiple Myeloma Market Challenges
 Table 15. Refractory Multiple Myeloma Market Restraints
 Table 16. Global Refractory Multiple Myeloma Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Refractory Multiple Myeloma Market Share by Players (2020-2025)
 Table 18. Global Top Refractory Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2024)
 Table 19. Ranking of Global Top Refractory Multiple Myeloma Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Refractory Multiple Myeloma Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Refractory Multiple Myeloma, Headquarters and Area Served
 Table 22. Global Key Players of Refractory Multiple Myeloma, Product and Application
 Table 23. Global Key Players of Refractory Multiple Myeloma, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Refractory Multiple Myeloma Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Refractory Multiple Myeloma Revenue Market Share by Type (2020-2025)
 Table 27. Global Refractory Multiple Myeloma Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Refractory Multiple Myeloma Revenue Market Share by Type (2026-2031)
 Table 29. Global Refractory Multiple Myeloma Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Refractory Multiple Myeloma Revenue Market Share by Application (2020-2025)
 Table 31. Global Refractory Multiple Myeloma Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Refractory Multiple Myeloma Revenue Market Share by Application (2026-2031)
 Table 33. North America Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Refractory Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Refractory Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Refractory Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Refractory Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Refractory Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Refractory Multiple Myeloma Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Refractory Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Refractory Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Refractory Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Refractory Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Bristol Myers Squibb Company Details
 Table 49. Bristol Myers Squibb Business Overview
 Table 50. Bristol Myers Squibb Refractory Multiple Myeloma Product
 Table 51. Bristol Myers Squibb Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 52. Bristol Myers Squibb Recent Development
 Table 53. Teva Pharmaceutical Industries Ltd. Company Details
 Table 54. Teva Pharmaceutical Industries Ltd. Business Overview
 Table 55. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product
 Table 56. Teva Pharmaceutical Industries Ltd. Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 57. Teva Pharmaceutical Industries Ltd. Recent Development
 Table 58. Pfizer Inc. Company Details
 Table 59. Pfizer Inc. Business Overview
 Table 60. Pfizer Inc. Refractory Multiple Myeloma Product
 Table 61. Pfizer Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 62. Pfizer Inc. Recent Development
 Table 63. Janssen Global Services, LLC Company Details
 Table 64. Janssen Global Services, LLC Business Overview
 Table 65. Janssen Global Services, LLC Refractory Multiple Myeloma Product
 Table 66. Janssen Global Services, LLC Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 67. Janssen Global Services, LLC Recent Development
 Table 68. Gilead Sciences, Inc. Company Details
 Table 69. Gilead Sciences, Inc. Business Overview
 Table 70. Gilead Sciences, Inc. Refractory Multiple Myeloma Product
 Table 71. Gilead Sciences, Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 72. Gilead Sciences, Inc. Recent Development
 Table 73. Fresenius Kabi Company Details
 Table 74. Fresenius Kabi Business Overview
 Table 75. Fresenius Kabi Refractory Multiple Myeloma Product
 Table 76. Fresenius Kabi Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 77. Fresenius Kabi Recent Development
 Table 78. GSK plc. Company Details
 Table 79. GSK plc. Business Overview
 Table 80. GSK plc. Refractory Multiple Myeloma Product
 Table 81. GSK plc. Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 82. GSK plc. Recent Development
 Table 83. Novartis AG Company Details
 Table 84. Novartis AG Business Overview
 Table 85. Novartis AG Refractory Multiple Myeloma Product
 Table 86. Novartis AG Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 87. Novartis AG Recent Development
 Table 88. Takeda Pharmaceutical Company Limited Company Details
 Table 89. Takeda Pharmaceutical Company Limited Business Overview
 Table 90. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product
 Table 91. Takeda Pharmaceutical Company Limited Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 92. Takeda Pharmaceutical Company Limited Recent Development
 Table 93. Genentech, Inc. Company Details
 Table 94. Genentech, Inc. Business Overview
 Table 95. Genentech, Inc. Refractory Multiple Myeloma Product
 Table 96. Genentech, Inc. Revenue in Refractory Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 97. Genentech, Inc. Recent Development
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Refractory Multiple Myeloma Picture
 Figure 2. Global Refractory Multiple Myeloma Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Refractory Multiple Myeloma Market Share by Type: 2024 VS 2031
 Figure 4. Proteosome Inhibitor Features
 Figure 5. Immunomodulators Features
 Figure 6. Anti-CD38 Monoclonal Antibody Features
 Figure 7. Others Features
 Figure 8. Global Refractory Multiple Myeloma Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Refractory Multiple Myeloma Market Share by Application: 2024 VS 2031
 Figure 10. Hospital Case Studies
 Figure 11. Specialty Clinic Case Studies
 Figure 12. Others Case Studies
 Figure 13. Refractory Multiple Myeloma Report Years Considered
 Figure 14. Global Refractory Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Refractory Multiple Myeloma Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Refractory Multiple Myeloma Market Share by Region: 2024 VS 2031
 Figure 17. Global Refractory Multiple Myeloma Market Share by Players in 2024
 Figure 18. Global Top Refractory Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Refractory Multiple Myeloma Revenue in 2024
 Figure 20. North America Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Refractory Multiple Myeloma Market Share by Country (2020-2031)
 Figure 22. United States Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Refractory Multiple Myeloma Market Share by Country (2020-2031)
 Figure 26. Germany Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Refractory Multiple Myeloma Market Share by Region (2020-2031)
 Figure 34. China Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Refractory Multiple Myeloma Market Share by Country (2020-2031)
 Figure 42. Mexico Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Refractory Multiple Myeloma Market Share by Country (2020-2031)
 Figure 46. Turkey Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Refractory Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Bristol Myers Squibb Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 50. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 51. Pfizer Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 52. Janssen Global Services, LLC Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 53. Gilead Sciences, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 54. Fresenius Kabi Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 55. GSK plc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 56. Novartis AG Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 57. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 58. Genentech, Inc. Revenue Growth Rate in Refractory Multiple Myeloma Business (2020-2025)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2024
Global Refractory Product Market Research Report 2024
Global Immunomodulator for Multiple Myeloma Market Research Report 2024
Global Refractory Magnesia Market Research Report 2025
Global Refractory Ball Market Research Report 2025
Global ImmunOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Bone Marrow Medium Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Proteasome Inhibitors for Multiple Myeloma Market Research Report 2024
Global Refractory Patch Market Research Report 2025
Global Targeted Drugs for Multiple Myeloma Market Research Report 2024
Global Myelodysplastic Syndrome Market Research Report 2024
Global Refractory Magnesia Raw Materials Market Research Report 2025
Global High Grade Refractory Market Research Report 2024
Global Refractory Alumina Market Research Report 2025
Hematologic Malignancies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Traditional ChemOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Global Plastic Refractory Market Research Report 2024
Global Refractory Coatings Market Research Report 2024
Multiple Myeloma Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Refractory Binders Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions